NHS approves new ovarian cancer drug that prolongs lives
In the UK, over 7,500 women are diagnosed with ovarian cancer every year. By 2040, it’s predicted this number will rise to 9,400. For more than 30 years, platinum-based chemotherapy…
How Medicare Advantage Rebates Disadvantage Medicare’s Stand-Alone Drug Plan Market
The Medicare Part D prescription drug benefit was designed to offer Medicare beneficiaries the choice of drug coverage from either stand-alone prescription drug plans (PDPs) for people in traditional Medicare…
Supreme Court Backs Maker of Generic Heart Drug in ‘Skinny Label’ Case
Amarin Pharma has not done enough to definitively show that its generic competitor, Hikma Pharmaceuticals, is infringing on Amarin’s patents for its anti-hypertriglyceridemia drug icosapent ethyl (Vascepa), the Supreme Court…
NHS England » NHS rolls out life-extending drug for hundreds of women with ovarian cancer
Hundreds of women with hard-to-treat ovarian cancer could benefit from a new, life-extending drug on the NHS from today – the first new addition to NHS treatment in over 20…
Environmental Factor – December 2025: Key protein serves as both an environmental sensor and drug target
When scientists investigated why dioxins caused such severe health effects, they uncovered a key player in the body’s response to many toxic chemicals. Their work led to the discovery of…
Don’t Blame DMARDs for Adverse Drug Effects in Rheumatology Patients
Adverse drug effects commonly occur in patients with rheumatologic diseases, most of whom take multiple medications to control their primary disease as well as for specific symptoms and comorbidities. The…
